Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Venetoclax bulk supplier for pharma manufacturers

Venetoclax 10 mg, 50 mg, 100 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 10 mg, 50 mg, 100 mg

Reference Brands: Venclexta® (EU & US)

Category: Oncology Cancer Care

Venetoclax Tablets (brand name Venclexta®) are oral BCL-2 inhibitors used for treating CLL, SLL, and AML. Available in 10 mg, 50 mg, and 100 mg strengths, they are manufactured under GMP standards and approved in US and EU markets, offering a reliable oncology solution.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Venetoclax Tablets are a targeted oral therapy used in the treatment of hematologic malignancies such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). As a potent BCL-2 inhibitor, Venetoclax promotes apoptosis in cancer cells by restoring programmed cell death pathways. Marketed under the brand name Venclexta®, it is available in 10 mg, 50 mg, and 100 mg strengths. Manufactured under GMP-certified facilities, Venetoclax offers a reliable oncology solution for B2B pharmaceutical partners across the US and EU, supporting effective cancer treatment strategies with proven clinical outcomes.

Venetoclax — third party manufacturing & bulk supply

Venetoclax 10 mg, 50 mg, 100 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Venetoclax is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Venetoclax listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Venetoclax →
Back to Listing

Frequently Asked Questions

Venetoclax is listed as Tablet in 10 mg, 50 mg, 100 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Venetoclax is referenced against Venclexta® (EU & US). Reference brands are shown for identification only and remain the property of their respective trademark owners.

Related Products

Acalabrutinib

Strength:
100 mg

Form: Oral Capsules

Reference Brands: Calquence® (EU & US)

View Details
Ixazomib

Strength:
2.3 mg, 3 mg, 4 mg

Form: Capsules

Reference Brands: Ninlaro® (EU & US)

View Details
Olaparib

Strength:
100 mg, 150 mg

Form: Tablet

Reference Brands: Lynparza® (US & EU)

View Details
Temozolomide 5 Mg Capsule

Strength:
Capsules: 5 mg, 20 mg, 100 mg, 140 mg; Tablets: 250 mg

Form: Oral Tablets and Oral Capsules

Reference Brands: Temodar® (US & EU)

View Details
Essential Trace Minerals With Lycopene Tablets

Strength:
30gm

Form: tablets

Reference Brands:

View Details
Anastrozole

Strength:
1mg

Form: Tablets

Reference Brands: Arimidex (US/EU)

View Details
Aprepitant

Strength:
125/80mg

Form: Capsules

Reference Brands: Emend (US/EU)

View Details
Axitinib

Strength:
1/5 mg

Form: Tablets

Reference Brands: Inlyta (US/EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.